NCT01351805 2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA Completed
Clinical Trials
27 trialsNCT03721172 2024-05-29
ADVANCE
Amgen
Phase 3 Completed
NCT00585650 2023-08-18
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
University of California, Irvine
Phase 1/2 Completed
NCT04571567 2022-04-11
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
Icahn School of Medicine at Mount Sinai
Phase 4 Completed
NCT02538341 2021-11-23
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
University of Alabama at Birmingham
Phase 2 Completed
NCT02762955 2021-09-08
CALYPSO
Biocad
Phase 3 Completed
NCT00885196 2020-12-22
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Novartis
Phase 2 Completed
NCT01490632 2019-09-27
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01107457 2019-09-24
A Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
Phase 2 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01961609 2019-03-18
SIGNATURE
Novartis
Phase 3 Completed
NCT02908347 2019-01-23
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
MetrioPharm AG
Phase 2 Completed
NCT01582932 2019-01-22
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Mayne Pharma International Pty Ltd
Phase 1 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT02196701 2018-03-19
CLEAR
AbbVie
Phase 3 Completed
NCT01053819 2018-02-23
Can We Miss Pigmented Lesions in Psoriasis Patients?
University of Alabama at Birmingham
Phase 4 Completed
NCT00932113 2017-08-31
MOA
Tufts Medical Center
Phase 4 Completed
NCT01313221 2017-03-15
REFINE
Amgen
Phase 3 Completed
NCT01831466 2015-11-25
Tofacitinib Ointment For Chronic Plaque Psoriasis
Pfizer
Phase 2 Completed
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01309737 2014-09-19
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00824889 2014-08-29
Exploratory Study of Natural Killer Cells in Human Skin
Assistance Publique Hopitaux De Marseille
Phase NA Completed
NCT00111449 2013-05-15
Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Amgen
Phase 3 Completed
NCT00111436 2013-04-26
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
Amgen
Phase 3 Completed
NCT01077882 2012-07-06
OnderHUIDs
University Hospital, Ghent
Phase 4 Completed